Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-05
DOI
10.1038/s41375-020-0842-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- High-risk additional chromosomal abnormalities at low blast counts herald death by CML
- (2020) Rüdiger Hehlmann et al. LEUKEMIA
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
- (2018) Bruno C. Medeiros et al. BLOOD REVIEWS
- Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
- (2018) Valentín García-Gutiérrez et al. ANNALS OF HEMATOLOGY
- First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI
- (2017) Giuseppe Saglio et al. LEUKEMIA & LYMPHOMA
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
- (2016) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
- (2016) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- The OPTIC Study: a Multi-Center, Randomized Phase 2 Trial with Response-Based Dose Reduction to Evaluate Three Starting Doses of Ponatinib
- (2016) Valentin García Gutierrez et al. Clinical Lymphoma Myeloma & Leukemia
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- Best Practices in Chronic Myeloid Leukemia Monitoring and Management
- (2016) Simona Soverini et al. ONCOLOGIST
- Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
- (2016) Simona Soverini et al. Oncotarget
- Chronic myeloid leukemia: Second-line drugs of choice
- (2015) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chronic myeloid leukemia: First-line drug of choice
- (2015) Elias Jabbour AMERICAN JOURNAL OF HEMATOLOGY
- A review of the European LeukemiaNet recommendations for the management of CML
- (2015) Michele Baccarani et al. ANNALS OF HEMATOLOGY
- Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience
- (2015) BF Ribeiro et al. Clinics
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
- (2012) Sara Redaelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?
- (2011) Jorge Cortes et al. Clinical Lymphoma Myeloma & Leukemia
- Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
- (2010) A. R. Ibrahim et al. BLOOD
- Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
- (2010) F J Giles et al. LEUKEMIA
- The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
- (2009) R. J. Garg et al. BLOOD
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
- (2009) D. Milojkovic et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now